JP5266051B2 - 大きい置換基を有する非フェノール性オピオイド - Google Patents
大きい置換基を有する非フェノール性オピオイド Download PDFInfo
- Publication number
- JP5266051B2 JP5266051B2 JP2008523037A JP2008523037A JP5266051B2 JP 5266051 B2 JP5266051 B2 JP 5266051B2 JP 2008523037 A JP2008523037 A JP 2008523037A JP 2008523037 A JP2008523037 A JP 2008523037A JP 5266051 B2 JP5266051 B2 JP 5266051B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen atom
- alkyl group
- halo
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000001424 substituent group Chemical group 0.000 title claims description 6
- 229940005483 opioid analgesics Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- -1 8-Substituted-2,6-methano-3-benzazocines Chemical class 0.000 claims abstract description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 64
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 44
- 125000005843 halogen group Chemical group 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000004414 alkyl thio group Chemical group 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical compound C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- ZJFPQVBARDXZPX-UHFFFAOYSA-N 2,6-methano-3-benzazocine Chemical class C1=CC=C2C(C3)=CC=NC3=CC2=C1 ZJFPQVBARDXZPX-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 125000005059 halophenyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- 125000003944 tolyl group Chemical group 0.000 claims description 4
- 208000004454 Hyperalgesia Diseases 0.000 claims description 3
- 208000035154 Hyperesthesia Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 2
- 206010038678 Respiratory depression Diseases 0.000 claims description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical group C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 claims description 2
- IYYZUPMFVPLQIF-ALWQSETLSA-N dibenzothiophene Chemical group C1=CC=CC=2[34S]C3=C(C=21)C=CC=C3 IYYZUPMFVPLQIF-ALWQSETLSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 4
- 238000010276 construction Methods 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 abstract description 5
- 229940124584 antitussives Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 229940125681 anticonvulsant agent Drugs 0.000 abstract description 4
- 239000001961 anticonvulsive agent Substances 0.000 abstract description 4
- 239000003434 antitussive agent Substances 0.000 abstract description 4
- 229940035676 analgesics Drugs 0.000 abstract description 3
- 239000000730 antalgic agent Substances 0.000 abstract description 3
- 239000003793 antidiarrheal agent Substances 0.000 abstract description 3
- 229940125714 antidiarrheal agent Drugs 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 206010012335 Dependence Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 32
- 238000000921 elemental analysis Methods 0.000 description 29
- 239000006260 foam Substances 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 17
- 102000003840 Opioid Receptors Human genes 0.000 description 16
- 108090000137 Opioid Receptors Proteins 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 230000027455 binding Effects 0.000 description 12
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- WHPLBPSDTIZFSX-UHFFFAOYSA-N 2-(4-phenylphenyl)ethanamine Chemical compound C1=CC(CCN)=CC=C1C1=CC=CC=C1 WHPLBPSDTIZFSX-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 229960005181 morphine Drugs 0.000 description 6
- 102000051367 mu Opioid Receptors Human genes 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 108020001612 μ-opioid receptors Proteins 0.000 description 6
- XBRXTUGRUXGBPX-DLBZAZTESA-N cyclazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N([C@@H]1CCCC[C@@H]11)CCN1C(=O)C1=CC=CO1 XBRXTUGRUXGBPX-DLBZAZTESA-N 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 4
- 229960003086 naltrexone Drugs 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 4
- 108020001588 κ-opioid receptors Proteins 0.000 description 4
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 3
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- WIYUZYBFCWCCQJ-IFKAHUTRSA-N Naltrindole Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3NC=25)O)CC1)O)CC1CC1 WIYUZYBFCWCCQJ-IFKAHUTRSA-N 0.000 description 3
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 3
- 108700023159 delta Opioid Receptors Proteins 0.000 description 3
- 102000048124 delta Opioid Receptors Human genes 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 2
- SEJUQQOPVAUETF-QHLBDZCJSA-N (2r,6r,11s)-3-(cyclopropylmethyl)-6-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2h)-one Chemical compound C([C@@]1([C@@H]([C@@H]2C(=O)C=3C1=CC(O)=CC=3)C)CC)CN2CC1CC1 SEJUQQOPVAUETF-QHLBDZCJSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- JHUYTXKVFLOJSS-UHFFFAOYSA-N 3-naphthalen-2-ylpropan-1-amine Chemical compound C1=CC=CC2=CC(CCCN)=CC=C21 JHUYTXKVFLOJSS-UHFFFAOYSA-N 0.000 description 2
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 150000003975 aryl alkyl amines Chemical class 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical group C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- YQYVFVRQLZMJKJ-OTLVQASYSA-N (-)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@H]2C1C)CN2CC1CC1 YQYVFVRQLZMJKJ-OTLVQASYSA-N 0.000 description 1
- BSVHTRRLCAVQCZ-JDEXMCKMSA-N (2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrro Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 BSVHTRRLCAVQCZ-JDEXMCKMSA-N 0.000 description 1
- RMSPOVPGDBDYKH-UHFFFAOYSA-N (4-phenylphenyl)methanamine Chemical compound C1=CC(CN)=CC=C1C1=CC=CC=C1 RMSPOVPGDBDYKH-UHFFFAOYSA-N 0.000 description 1
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical group C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WEERVPDNCOGWJF-UHFFFAOYSA-N 1,4-bis(ethenyl)benzene Chemical group C=CC1=CC=C(C=C)C=C1 WEERVPDNCOGWJF-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- ITRNQMJXZUWZQL-UHFFFAOYSA-N 2-(2-bromophenyl)ethanamine Chemical compound NCCC1=CC=CC=C1Br ITRNQMJXZUWZQL-UHFFFAOYSA-N 0.000 description 1
- OZUNHSMQAVTNLW-UHFFFAOYSA-N 2-(2-phenoxyphenyl)ethanamine Chemical compound NCCC1=CC=CC=C1OC1=CC=CC=C1 OZUNHSMQAVTNLW-UHFFFAOYSA-N 0.000 description 1
- ORHRHMLEFQBHND-UHFFFAOYSA-N 2-(3-bromophenyl)ethanamine Chemical compound NCCC1=CC=CC(Br)=C1 ORHRHMLEFQBHND-UHFFFAOYSA-N 0.000 description 1
- CNALSZKXQUFGDN-UHFFFAOYSA-N 2-(3-phenoxyphenyl)ethanamine Chemical compound NCCC1=CC=CC(OC=2C=CC=CC=2)=C1 CNALSZKXQUFGDN-UHFFFAOYSA-N 0.000 description 1
- XHDHLKZCOPJXJZ-UHFFFAOYSA-N 2-(4-benzylphenyl)ethanamine Chemical compound C1=CC(CCN)=CC=C1CC1=CC=CC=C1 XHDHLKZCOPJXJZ-UHFFFAOYSA-N 0.000 description 1
- ZSZCXAOQVBEPME-UHFFFAOYSA-N 2-(4-bromophenyl)ethanamine Chemical compound NCCC1=CC=C(Br)C=C1 ZSZCXAOQVBEPME-UHFFFAOYSA-N 0.000 description 1
- JNHPLGDXCJAUBX-UHFFFAOYSA-N 2-(4-phenoxyphenyl)ethanamine Chemical compound C1=CC(CCN)=CC=C1OC1=CC=CC=C1 JNHPLGDXCJAUBX-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- RUJHATQMIMUYKD-UHFFFAOYSA-N 2-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C(CCN)=CC=CC2=C1 RUJHATQMIMUYKD-UHFFFAOYSA-N 0.000 description 1
- ZOBYXAWBGJRPRG-UHFFFAOYSA-N 2-naphthalen-2-ylethanamine Chemical compound C1=CC=CC2=CC(CCN)=CC=C21 ZOBYXAWBGJRPRG-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical group OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- QNMNMNZGJJDCSG-UHFFFAOYSA-N 3-(4-phenylphenyl)prop-2-enamide Chemical compound C1=CC(C=CC(=O)N)=CC=C1C1=CC=CC=C1 QNMNMNZGJJDCSG-UHFFFAOYSA-N 0.000 description 1
- QMAHVAFURJBOFV-UHFFFAOYSA-N 4-(bromomethyl)-3-nitrobenzoic acid Chemical group OC(=O)C1=CC=C(CBr)C([N+]([O-])=O)=C1 QMAHVAFURJBOFV-UHFFFAOYSA-N 0.000 description 1
- KQWVAUSXZDRQPZ-UMTXDNHDSA-N 4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enyl-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1[C@H](C=1C=C(OC)C=CC=1)N1[C@@H](C)CN(CC=C)[C@H](C)C1 KQWVAUSXZDRQPZ-UMTXDNHDSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 108010077495 Peptide oostatic hormone Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000396922 Pontia daplidice Species 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229950002213 cyclazocine Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical compound [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000002632 kappa opiate receptor agonist Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000002756 mu opiate receptor agonist Substances 0.000 description 1
- VLKFAIHXYCUNJA-UHFFFAOYSA-N n-methyl-2-(4-phenylphenyl)ethanamine Chemical compound C1=CC(CCNC)=CC=C1C1=CC=CC=C1 VLKFAIHXYCUNJA-UHFFFAOYSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 230000000945 opiatelike Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003859 secondary carboxamides Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Chemical group 0.000 description 1
- 230000031143 xenobiotic glucuronidation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Aは、(CH2)n(式中、1以上のCH2を−O−、シクロアルキル基又は−CR1aR1bにより置き換えることができる)であり;
R1a及びR1bは、独立して、水素原子、ハロゲン原子、低級アルキル基、低級アルコキシ基及び低級アルキルチオ基から選択され;
R2及びR2aは、両方共に水素原子であるか、又はR2及びR2aが一緒になって=Oであり;
R3は、水素原子、C1〜C8炭化水素基、ヘテロシクリル基、ヘテロシクリルアルキル基及びヒドロキシアルキル基から選択され;
R4は、水素原子、ヒドロキシ基、アミノ基、低級アルコキシ基、C1〜C20アルキル基、及びヒドロキシ基又はカルボニル基で置換されるC1〜C20アルキル基から選択され;
R5は、低級アルキル基であり;
R6は、低級アルキル基であり;
R7は、水素原子及びヒドロキシ基から選択され;又は
R4、R5、R6及びR7が一緒になって1〜3個の環を形成することができ、前記環が場合により、付加的置換基を有し;
R10は、独立して、水素原子、ヒドロキシル基、ハロゲン原子、(C1〜C6)アルキル基、(C1〜C6)アルコキシ基、ハロ(C1〜C6)アルキル基及びハロ(C1〜C6)アルコキシ基並びに(C1〜C6)アルキルチオ基から選択される1つ又は2つの残基であり;
R11は、H又は
A’は、(CH2)m(式中、1以上のCH2を−O−、シクロアルキル基、−CR1aR1b、−C(=O)−又は−NH−により置き換えることができる)であり;
R12は、水素原子及び低級アルキル基から選択され;
R15は、独立して、水素原子、ヒドロキシル基、ハロゲン原子、(C1〜C6)アルキル基、(C1〜C6)アルコキシ基、ハロ(C1〜C6)アルキル基及びハロ(C1〜C6)アルコキシ基並びに(C1〜C6)アルキルチオ基から選択される1つ又は2つの残基であり;
mは、0又は1〜6の整数であり;並びに
nは、1〜6の整数である)
で表される化合物に関する。
II. R4、R5、R6及びR7が付加的な環を形成しない、上に示す構造で表される2,6−メタノ−3−ベンゾアゾシン類:
R3aは、水素原子、C1〜C7炭化水素基、ヘテロシクリル基、及びヒドロキシアルキル基から選択され;
R4は、水素原子、ヒドロキシ基、低級アルコキシ基、C1〜C20アルキル基、及びヒドロキシ基又はカルボニル基で置換されるC1〜C20アルキル基から選択され;
R5は、低級アルキル基であり;
R6は、低級アルキル基であり;並びに
R7は、水素原子又はヒドロキシ基である)
III. R5及びR6が1つの環を形成するモルフィナン類:
R3aは、水素原子、C1〜C7炭化水素基、ヘテロシクリル基、及びヒドロキシアルキル基から選択され;並びにR7は、H又はOHである)
IV. R5、R6及びR7が2つの環を形成するモルフィナン類:
R19は、水素原子又は低級アルキル基であり;
R20は、水素原子、低級アルキル基及びヒドロキシ(低級アルキル)基から選択され;又はR 19 及びR 20 が一緒になって炭素原子5〜10個のスピロ縮合炭素環を形成し;
R21は、水素原子であり;
R22は、ヒドロキシ基、低級アルコキシ基及び−NR13R14から選択され;又は
R21及びR22が一緒になってカルボニル基又はビニル置換基を形成する)
並びに
V. R4及びR11が飽和又は不飽和であることができる第6の環を更に形成するモルフィナン類:
(a)オピオイド受容体応答を阻害する、引き出す又は高める第1の化合物を準備すること;
(b)第1の化合物上のフェノール性ヒドロキシル基を上のQとして記載される残基に変換することにより、オピオイド受容体と相互に作用する第2の化合物を製造すること;及び
(c)第2の化合物をオピオイド受容体と接触させることを含む方法に関する。
(a)
(b)
(c)
本明細書の全体にわたり、用語及び置換基はその定義を保持する。
次の略語及び用語は、全体にわたり指示された意味を有する。
Ac = アセチル
BNB = 4−ブロモメチル−3−ニトロ安息香酸
Boc = t−ブチルオキシカルボニル
Bu = ブチル
c− = シクロ
DAMGO = Tyr−ala−Gly−NMePhe−NHCH2OH
DBU = ジアザビシクロ[5.4.0]ウンデク−7−エン
DCM = ジクロロメタン=塩化メチレン=CH2Cl2
DEAD = アゾジカルボン酸ジエチル
DIC = ジイソプロピルカルボジイミド
DIEA = N,N−ジイソプロピルエチルアミン
DMAP = 4−N,N−ジメチルアミノピリジン
DMF = N,N−ジメチルホルムアミド
DMSO = ジメチルスルホキシド
DPPF = 1,1’−ビス(ジフェニルホスフィノ)フェロセン
DVB = 1,4−ジビニルベンゼン
EEDQ = 2−エトキシ−1−エトキシカルボニル−1,2−ジヒドロキノリン
Fmoc = 9−フルオレニルメトキシカルボニル
GC = ガスクロマトグラフィー
HATU = ヘキサフルオロリン酸O−(7−アザベンゾトリアゾール−1−イル)−1,1,3,3−テトラメチルウロニウム
HOAc = 酢酸
HOBt = ヒドロキシベンゾトリアゾール
Me = メチル
mesyl = メタンスルホニル
MTBE = メチルt−ブチルエーテル
NMO = N−メチルモルホリンオキシド
PEG = ポリエチレングリコール
Ph = フェニル
PhOH = フェノール
PfP = ペンタフルオロフェノール
PPTS = p−トルエンスルホン酸ピリジニウム
PyBroP= ヘキサフルオロリン酸ブロモ−トリス−ピロリジノ−ホスホニウム
rt = 室温
sat’d = 飽和
s− = 第二級
t− = 第三級
TBDMS = t−ブチルジメチルシリル
TFA = トリフルオロ酢酸
THF = テトラヒドロフラン
TMOF = オルトギ酸トリメチル
TMS = トリメチルシリル
tosyl = p−トルエンスルホニル
Trt = トリフェニルメチル
U69,593=
方法A。Wentland et al.[Bioorgan.Med.Chem.Lett.2001,11,623−626]により以前に報告された条件と同様の条件を用いた。乾燥ピリジン2.5mL中の(±)−3(140mg,0.35mmol)及び2−(4−ビフェニルエチルアミン)(84mg,0.42mmol)の溶液を、室温で48時間撹拌した。溶媒を真空下に除去し、残渣を塩化メチレン(40mL)中に溶解して、飽和重炭酸ナトリウム溶液、水、及びブラインで1回洗浄した。有機相を硫酸ナトリウムで乾燥し、濾過し、濃縮して、褐色残渣を得、これをフラッシュクロマトグラフィー(CH2Cl2:CH3OH:NH4OH 15:1:0.1)により精製して、15を灰色がかった白色泡状物(110mg,0.23mmol,66%)として得た。1HNMR(500MHz,CDCl3)δ7.66(d,1H,J=1.5Hz),7.57(dd,2H,J1=1.3Hz,J2=7.5Hz),7.55(d,2H,J=8.5Hz),7.43(t,2H,J=7.75Hz),7.39(dd,1H,J1=1.8Hz,J2=7.75Hz),7.34(t,1H,J=7.5Hz),7.31(d,2H,J=8Hz),7.08(d,1H,J=8Hz),6.32(bt,1H,J=5.75Hz),3.72(q,2H,J=6.7Hz),3.14(m,1H),2.97(t,2H,J=1.5Hz),2.93(d,1H,J=18.5Hz),2.70(m,2H),2.45(dd,1H,J1=6.3Hz,J2=12.75Hz),2.34(dd,1H,J1=6.75Hz,J2=12.75Hz),1.93(m,3H),1.39(s,3H),1.32(d,1H,J=9.5),0.87(m,1H),0.81(d,3H,J=7.0Hz),0.50(dd,2H,J1=1.5Hz,J2=8.0Hz),0.12(m,2H).MS(ESI)m/z479(M+H)+;元素分析 C33H38N2O・1.0H2Oに対する計算値:C79.80,H8.12,N5.64.実測値:C79.72,H8.07,N5.96.
方法B。以前に報告された条件と同様の条件を用いた。2−(4−ビフェニルエチルアミン)(85mg,0.43mmol)PdCl2(dppf)(16mg,0.02mmol)を、(−)−シクラゾシン5のトリフレートエステル(158mg,0.39mmol)が入った二口フラスコに添加した。反応容器は冷却器を備え、セプタム及び風船で封をした。システム全体を真空にし、窒素で再充填することを3回繰り返した。DMF(2mL)及びトリエチルアミン(0.09mL,0.62mmol)を、注射器により添加した。次いで、再び真空にして、一酸化炭素混合物で再充填した。得られた混合物を70℃で18時間加熱した。冷却した反応混合物を酢酸エチル(30mL)で希釈して、飽和重炭酸塩溶液、水、及びブラインで洗浄した。有機相を硫酸ナトリウムで乾燥し、濾過し、濃縮して、黒色油状物を得、これを、フラッシュクロマトグラフィー(CH2Cl2:CH3OH:NH4OH 25:1:0.1)により精製して、(−)−16を灰色がかった白色泡状物(100mg,0.21mmol,53%)として得た。1HNMR(300MHz,CDCl3)δ7.68(s,1H),7.57(m,4H),7.43(m,3H),7.33(m,3H),7.08(d,1H,J=7.8Hz),6.34(bt,1H),3.73(q,2H,J=6.0Hz),3.16(m,1H),2.94(m,3H),2.71(m,2H),2.48(m,1H),2.31(m,1H),1.93(m,3H),1.40(s,3H),1.32(m,1H),0.87(m,1H),0.82(d,3H,J=7.2Hz),0.51(d,2H,J=6.6Hz),0.11(m,2H).MS(ESI)m/z479(M+H)+;元素分析 C33H38N2O・1.25H2Oに対する計算値:C79.08,H8.14,N5.59.実測値:C79.23,H7.84,N5.57.(−)−16について:[α]25 D=−69.1o(c=.75,アセトン).
Claims (15)
- 式:
Aは、(CH 2 ) n (式中、1以上のCH 2 を−O−、シクロアルキル基又は−CR 1a R 1b により置き換えることができる)であり;
R 1a 及びR 1b は、独立して、水素原子、ハロゲン原子、低級アルキル基、低級アルコキシ基及び低級アルキルチオ基から選択され;
R 2 及びR 2a は、両方共に水素原子であるか、又はR 2 及びR 2a が一緒になって=Oであり;
R3aは、水素原子、C1〜C7炭化水素基、ヘテロシクリル基、及びヒドロキシアルキル基から選択され;
R4は、水素原子、ヒドロキシ基、低級アルコキシ基、C1〜C20アルキル基、及びヒドロキシ基又はカルボニル基で置換されるC1〜C20アルキル基から選択され;
R5は、低級アルキル基であり;
R6は、低級アルキル基であり;
R 7は、水素原子又はヒドロキシ基であり、
R 10 は、独立して、水素原子、ヒドロキシル基、ハロゲン原子、(C 1 〜C 6 )アルキル基、(C 1 〜C 6 )アルコキシ基、ハロ(C 1 〜C 6 )アルキル基及びハロ(C 1 〜C 6 )アルコキシ基並びに(C 1 〜C 6 )アルキルチオ基から選択される1つ又は2つの残基であり;
R 11 は、H又は
A’は、(CH 2 ) m (式中、1以上のCH 2 を−O−、シクロアルキル基、−CR 1a R 1b 、−C(=O)−又は−NH−により置き換えることができる)であり;
R 12 は、水素原子及び低級アルキル基から選択され;
R 15 は、独立して、水素原子、ヒドロキシル基、ハロゲン原子、(C 1 〜C 6 )アルキル基、(C 1 〜C 6 )アルコキシ基、ハロ(C 1 〜C 6 )アルキル基及びハロ(C 1 〜C 6 )アルコキシ基並びに(C 1 〜C 6 )アルキルチオ基から選択される1つ又は2つの残基であり;
mは、0又は1〜6の整数であり;並びに
nは、1〜6の整数であるが;
但し、Aは、CH 2 ではないものとする)
で表される、2,6−メタノ−3−ベンゾアゾシン。 - R3aが、水素原子、シクロプロピル基、シクロブチル基、フェニル基、ビニル基、ジメチルビニル基、ヒドロキシシクロプロピル基、フラニル基、及びテトラヒドロフラニル基から選択され;
R4が、水素原子及び3−オキソ−5−シクロペンチル−1−ペンタニル基から選択され;
R5が、メチル基であり;並びに
R6が、メチル基又はエチル基である、請求項1に記載の2,6−メタノ−3−ベンゾアゾシン。 - 構造:
Aは、(CH 2 ) n (式中、1以上のCH 2 を−O−、シクロアルキル基又は−CR 1a R 1b により置き換えることができる)であり;
R 1a 及びR 1b は、独立して、水素原子、ハロゲン原子、低級アルキル基、低級アルコキシ基及び低級アルキルチオ基から選択され;
R 2 及びR 2a は、両方共に水素原子であるか、又はR 2 及びR 2a が一緒になって=Oであり;
R3aは、水素原子、C1〜C7炭化水素基、ヘテロシクリル基、及びヒドロキシアルキル基から選択され;
R 4 は、水素原子、ヒドロキシ基、低級アルコキシ基、C 1 〜C 20 アルキル基、及びヒドロキシ基又はカルボニル基で置換されるC 1 〜C 20 アルキル基から選択され;
R7は、H又はOHであり、
R 10 は、独立して、水素原子、ヒドロキシル基、ハロゲン原子、(C 1 〜C 6 )アルキル基、(C 1 〜C 6 )アルコキシ基、ハロ(C 1 〜C 6 )アルキル基及びハロ(C 1 〜C 6 )アルコキシ基並びに(C 1 〜C 6 )アルキルチオ基から選択される1つ又は2つの残基であり;
R 11 は、H又は
A’は、(CH 2 ) m (式中、1以上のCH 2 を−O−、シクロアルキル基、−CR 1a R 1b 、−C(=O)−又は−NH−により置き換えることができる)であり;
R 12 は、水素原子及び低級アルキル基から選択され;
R 15 は、独立して、水素原子、ヒドロキシル基、ハロゲン原子、(C 1 〜C 6 )アルキル基、(C 1 〜C 6 )アルコキシ基、ハロ(C 1 〜C 6 )アルキル基及びハロ(C 1 〜C 6 )アルコキシ基並びに(C 1 〜C 6 )アルキルチオ基から選択される1つ又は2つの残基であり;
mは、0又は1〜6の整数であり;並びに
nは、1〜6の整数であるが;
但し、Aは、CH 2 ではないものとする)
を有する、モルフィナン。 - R2及びR2aが、水素原子であり;
R3a が、水素原子、シクロプロピル基、シクロブチル基、ビニル基及びテトラヒドロフラニル基から選択され;並びに
R4が、水素原子、ヒドロキシ基又はアミノ基である、請求項4に記載のモルフィナン。 - 構造:
Aは、(CH 2 ) n (式中、1以上のCH 2 を−O−、シクロアルキル基又は−CR 1a R 1b により置き換えることができる)であり;
R 1a 及びR 1b は、独立して、水素原子、ハロゲン原子、低級アルキル基、低級アルコキシ基及び低級アルキルチオ基から選択され;
R 2 及びR 2a は、両方共に水素原子であるか、又はR 2 及びR 2a が一緒になって=Oであり;
R3aは、水素原子、C1〜C7炭化水素基、ヘテロシクリル基、及びヒドロキシアルキル基から選択され;
R4は、水素原子、ヒドロキシ基、アミノ基又は低級アルコキシ基であり;
R 10 は、独立して、水素原子、ヒドロキシル基、ハロゲン原子、(C 1 〜C 6 )アルキル基、(C 1 〜C 6 )アルコキシ基、ハロ(C 1 〜C 6 )アルキル基及びハロ(C 1 〜C 6 )アルコキシ基並びに(C 1 〜C 6 )アルキルチオ基から選択される1つ又は2つの残基であり;
R 11 は、H又は
A’は、(CH 2 ) m (式中、1以上のCH 2 を−O−、シクロアルキル基、−CR 1a R 1b 、−C(=O)−又は−NH−により置き換えることができる)であり;
R 12 は、水素原子及び低級アルキル基から選択され;
R 15 は、独立して、水素原子、ヒドロキシル基、ハロゲン原子、(C 1 〜C 6 )アルキル基、(C 1 〜C 6 )アルコキシ基、ハロ(C 1 〜C 6 )アルキル基及びハロ(C 1 〜C 6 )アルコキシ基並びに(C 1 〜C 6 )アルキルチオ基から選択される1つ又は2つの残基であり;
mは、0又は1〜6の整数であり;
nは、1〜6の整数であり;
R19は、水素原子又は低級アルキル基であり;
R20は、水素原子、低級アルキル基及びヒドロキシ(低級アルキル)基から選択され;又は
R19及びR20が一緒になって炭素原子5〜10個のスピロ縮合炭素環を形成し;
R21は、水素原子であり;
R22は、ヒドロキシ基、及び低級アルコキシ基から選択され;又は
R21及びR22が一緒になってカルボニル基又はビニル置換基を形成し;又は
R4及びR21が一緒になって第6の環を形成するが;
但し、Aは、CH 2 ではないものとする)
を有する、化合物。 - nが2である、請求項1〜8のいずれか一項に記載の化合物。
- 式:
Aは、(CH 2 ) n (式中、1以上のCH 2 を−O−、シクロアルキル基又は−CR 1a R 1b により置き換えることができる)であり;
R 1a 及びR 1b は、独立して、水素原子、ハロゲン原子、低級アルキル基、低級アルコキシ基及び低級アルキルチオ基から選択され;
R 2 及びR 2a は、両方共に水素原子であるか、又はR 2 及びR 2a が一緒になって=Oであり;
R 3 は、水素原子、C 1 〜C 8 炭化水素基、ヘテロシクリル基、ヘテロシクリルアルキル基及びヒドロキシアルキル基から選択され;
R 4 は、水素原子、ヒドロキシ基、アミノ基、低級アルコキシ基、C 1 〜C 20 アルキル基、及びヒドロキシ基又はカルボニル基で置換されるC 1 〜C 20 アルキル基から選択され;
R 7 は、水素原子及びヒドロキシ基から選択され;
R 10 は、独立して、水素原子、ヒドロキシル基、ハロゲン原子、(C 1 〜C 6 )アルキル基、(C 1 〜C 6 )アルコキシ基、ハロ(C 1 〜C 6 )アルキル基及びハロ(C 1 〜C 6 )アルコキシ基並びに(C 1 〜C 6 )アルキルチオ基から選択される1つ又は2つの残基であり;
R 11 は、H又は
A’は、(CH 2 ) m (式中、1以上のCH 2 を−O−、シクロアルキル基、−CR 1a R 1b 、−C(=O)−又は−NH−により置き換えることができる)であり;
R 12 は、水素原子及び低級アルキル基から選択され;
R 15 は、独立して、水素原子、ヒドロキシル基、ハロゲン原子、(C 1 〜C 6 )アルキル基、(C 1 〜C 6 )アルコキシ基、ハロ(C 1 〜C 6 )アルキル基及びハロ(C 1 〜C 6 )アルコキシ基並びに(C 1 〜C 6 )アルキルチオ基から選択される1つ又は2つの残基であり;
mは、0又は1〜6の整数であり;並びに
nは、1〜6の整数であるが;
但し、Aは、CH 2 ではないものとし;
R5及びR6が一緒になって1個の炭素環式環を形成し、前記環が場合により、ハロゲン原子、ヒドロキシル基、低級アルコキシ基、カルボキシ基、シアノ基、カルボニル基、ビニル基、−NH2基、又は−OCH3基から選択される付加的置換基を有する)
で表される、化合物。 - 前記環が6員の炭素環式環である、請求項13に記載の化合物。
- 痛み、かゆみ、下痢、過敏性腸症候群、胃腸運動障害、肥満症、呼吸抑制、痙攣、咳、痛覚過敏、運動障害及び薬物嗜癖からなる群から選択される疾患を治療するための組成物の製造における、請求項1〜14のいずれか一項に記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70140705P | 2005-07-21 | 2005-07-21 | |
US60/701,407 | 2005-07-21 | ||
PCT/US2006/028634 WO2007014137A2 (en) | 2005-07-21 | 2006-07-21 | 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009502808A JP2009502808A (ja) | 2009-01-29 |
JP2009502808A5 JP2009502808A5 (ja) | 2009-09-10 |
JP5266051B2 true JP5266051B2 (ja) | 2013-08-21 |
Family
ID=37622091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008523037A Active JP5266051B2 (ja) | 2005-07-21 | 2006-07-21 | 大きい置換基を有する非フェノール性オピオイド |
Country Status (7)
Country | Link |
---|---|
US (6) | US7557119B2 (ja) |
EP (2) | EP2266959B1 (ja) |
JP (1) | JP5266051B2 (ja) |
AU (1) | AU2006272773B2 (ja) |
CA (1) | CA2615774C (ja) |
ES (2) | ES2422579T3 (ja) |
WO (1) | WO2007014137A2 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1353909B1 (en) | 2000-10-31 | 2005-04-06 | Rensselaer Polytechnic Institute | 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents |
US7557119B2 (en) | 2005-07-21 | 2009-07-07 | Rensselaer Polytechnic Institute | Large substituent, non-phenolic opioids |
ES2586245T3 (es) | 2007-08-09 | 2016-10-13 | Rensselaer Polytechnic Institute | Carboxamidas cuaternarias opioides |
EP2318372B9 (en) * | 2008-07-21 | 2015-05-06 | Rensselaer Polytechnic Institute | Large substituent, non-phenolic amine opioids |
US8946419B2 (en) | 2009-02-23 | 2015-02-03 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
CN102325775A (zh) * | 2009-02-23 | 2012-01-18 | 马林克罗特公司 | (+)-6-羟基-吗啡喃或(+)-6-氨基-吗啡喃衍生物 |
NZ600379A (en) | 2009-12-04 | 2014-05-30 | Alkermes Pharma Ireland Ltd | Morphinan derivatives for the treatment of drug overdose |
JP5964809B2 (ja) * | 2010-03-22 | 2016-08-03 | レンセラール ポリテクニック インスティチュート | オピオイド受容体リガンドとしてのカルボキサミド基を含有するモルヒネ誘導体 |
ES2708726T3 (es) | 2010-07-08 | 2019-04-10 | Alkermes Pharma Ireland Ltd | Proceso para la síntesis de morfinanos sustituidos |
CA2807965C (en) | 2010-08-23 | 2016-03-15 | Alkermes Pharma Ireland Limited | Methods for treating antipsychotic-induced weight gain |
WO2012138888A1 (en) | 2011-04-05 | 2012-10-11 | Alkermes, Inc. | Process for the synthesis of quaternary amine compounds |
LT2725908T (lt) | 2011-06-29 | 2017-09-11 | Alkermes, Inc. | Periferinio poveikio opioidų junginiai |
US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
US9656961B2 (en) | 2013-05-24 | 2017-05-23 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
CA2911231C (en) | 2013-05-24 | 2021-12-07 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
CN103992272B (zh) * | 2014-06-09 | 2016-05-11 | 安徽省逸欣铭医药科技有限公司 | 一种盐酸喷他佐辛酯、其制备方法及其用途 |
CN109288840A (zh) * | 2018-11-23 | 2019-02-01 | 中国科学院长春应用化学研究所 | 二元纳曲酮衍生物的应用 |
TWI719740B (zh) * | 2019-12-04 | 2021-02-21 | 大江生醫股份有限公司 | 植物發酵物的製備方法、以及該發酵物及其活性成分的應用 |
EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9912411D0 (en) * | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
DE10038709A1 (de) * | 2000-08-09 | 2002-02-28 | Aventis Pharma Gmbh | Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen |
EP1353909B1 (en) * | 2000-10-31 | 2005-04-06 | Rensselaer Polytechnic Institute | 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents |
AU2003281060A1 (en) | 2002-07-16 | 2004-02-02 | Rensselaer Polytechnic Institute | Process for conversion of phenols to carboxamides via the succinimide esters |
WO2004013120A1 (en) * | 2002-07-29 | 2004-02-12 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
WO2005042491A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
KR20080027216A (ko) * | 2004-08-05 | 2008-03-26 | 얀센 파마슈티카 엔.브이. | 트리사이클릭 δ-오피오이드 조절자 |
KR101115841B1 (ko) | 2004-11-05 | 2012-03-09 | 렌슬러 폴리테크닉 인스티튜트 | 4-하이드록시벤조모르판 |
CA2591963A1 (en) | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | Tricyclic o-opioid modulators |
WO2006138528A2 (en) * | 2005-06-16 | 2006-12-28 | Janssen Pharmaceutica N.V | Tricyclic opioid modulators |
US7557119B2 (en) * | 2005-07-21 | 2009-07-07 | Rensselaer Polytechnic Institute | Large substituent, non-phenolic opioids |
JP5964809B2 (ja) * | 2010-03-22 | 2016-08-03 | レンセラール ポリテクニック インスティチュート | オピオイド受容体リガンドとしてのカルボキサミド基を含有するモルヒネ誘導体 |
-
2006
- 2006-07-21 US US11/459,203 patent/US7557119B2/en active Active
- 2006-07-21 CA CA2615774A patent/CA2615774C/en active Active
- 2006-07-21 ES ES10006594T patent/ES2422579T3/es active Active
- 2006-07-21 ES ES06800266.6T patent/ES2480390T3/es active Active
- 2006-07-21 AU AU2006272773A patent/AU2006272773B2/en active Active
- 2006-07-21 EP EP10006594.5A patent/EP2266959B1/en active Active
- 2006-07-21 JP JP2008523037A patent/JP5266051B2/ja active Active
- 2006-07-21 WO PCT/US2006/028634 patent/WO2007014137A2/en active Application Filing
- 2006-07-21 EP EP06800266.6A patent/EP1924559B1/en active Active
-
2009
- 2009-06-03 US US12/477,223 patent/US8026252B2/en active Active
-
2011
- 2011-08-23 US US13/215,392 patent/US8541586B2/en active Active
-
2013
- 2013-08-23 US US13/974,216 patent/US8901148B2/en active Active
-
2014
- 2014-10-31 US US14/529,832 patent/US9156821B2/en active Active
-
2015
- 2015-10-08 US US14/878,526 patent/US20160257677A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2615774C (en) | 2014-12-09 |
US20130345251A1 (en) | 2013-12-26 |
US8026252B2 (en) | 2011-09-27 |
US8541586B2 (en) | 2013-09-24 |
ES2480390T3 (es) | 2014-07-28 |
US20160257677A1 (en) | 2016-09-08 |
JP2009502808A (ja) | 2009-01-29 |
US20090247562A1 (en) | 2009-10-01 |
ES2422579T3 (es) | 2013-09-12 |
US20110306603A1 (en) | 2011-12-15 |
US20150051194A1 (en) | 2015-02-19 |
US20070021457A1 (en) | 2007-01-25 |
EP2266959B1 (en) | 2013-05-01 |
US7557119B2 (en) | 2009-07-07 |
CA2615774A1 (en) | 2007-02-01 |
EP1924559B1 (en) | 2014-04-16 |
EP2266959A1 (en) | 2010-12-29 |
EP1924559A2 (en) | 2008-05-28 |
US9156821B2 (en) | 2015-10-13 |
WO2007014137A3 (en) | 2007-03-29 |
WO2007014137A2 (en) | 2007-02-01 |
US8901148B2 (en) | 2014-12-02 |
AU2006272773A1 (en) | 2007-02-01 |
AU2006272773B2 (en) | 2012-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5266051B2 (ja) | 大きい置換基を有する非フェノール性オピオイド | |
EP1944292B9 (en) | 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents | |
EP2251330B1 (en) | 4-Hydroxybenzomorphans | |
JP2010535814A (ja) | 第四級オピオイドカルボキサミド | |
JP2010527374A (ja) | 縮合環複素環オピオイド | |
JP5727374B2 (ja) | 大型置換基を有する非フェノール性アミンオピオイド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090721 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090721 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120321 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120621 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120827 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130225 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130409 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130502 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5266051 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |